ATAI Stock Analysis: Buy, Sell, or Hold?
ATAI - ATAI Life Sciences N.V. Common Shares
$3.79
0.09 (2.43%)
▲
5d:
+7.06%
30d:
+2.71%
90d:
-7.33%
BUY
HIGH Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 13, 2026
Smart Money Accumulation
ATAI is down 8.8% this week, but smart money is accumulating calls. Top strike: $4 2026-05-15 with 2,216 OI. Call ratio: 86% View Scanner →
Strength: 7.9/10
Get Alerted When ATAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ATAI shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: ATAI shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: ATAI is currently trading at $3.79, which is considered fair relative to its 30-day fair value range of $3.43 to $3.96.
Technical Outlook: Technically, ATAI is in a strong uptrend. The price is approaching resistance at $3.80. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ATAI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $13.33 (+251.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ATAI is in a strong uptrend. The price is approaching resistance at $3.80. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ATAI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $13.33 (+251.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$3.43 -
$3.96
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
86.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 251.8% below Wall St target ($13.33)
Fair Price Analysis
30-Day Fair Range
$3.43 -
$3.96
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$3.27
Resistance Level
$3.80
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.80
Wall Street Target
$13.33
(+251.8%)
Revenue Growth (YoY)
1772.5%
Earnings Growth (YoY)
-96.8%
Share & Embed Analysis
Last updated: April 04, 2026 6:49 AM ET
Data refreshes hourly during market hours. Next update: 7:49 AM
Data refreshes hourly during market hours. Next update: 7:49 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 62 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 59 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 66 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 51 HOLD |
